Live price temporarily unavailable.
ALX Oncology Holdings (ALXO) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.07M | $4.80M | $1.18M | $0 | $0 | — | — | — |
| Growth (year over year) | — | +132.0% | −75.4% | −100.0% | — | — | — | — |
| Operating income | −$13.7M | −$19.2M | −$43.7M | −$83.6M | −$127.4M | −$170.3M | −$142.5M | −$104.0M |
| Operating margin | −662.0% | −400.0% | −3694.0% | — | — | — | — | — |
| Net income | −$13.7M | −$19.2M | −$45.7M | −$83.5M | −$123.5M | −$160.8M | −$134.8M | −$101.7M |
| Net margin | −664.3% | −401.2% | −3869.7% | — | — | — | — | — |
| EPS (diluted) | −$6.33 | −$7.56 | −$2.76 | −$2.07 | −$3.03 | −$3.74 | −$2.58 | −$1.90 |
| Balance sheet | ||||||||
| Cash and equivalents | $8.26M | $9.02M | $434.2M | $363.7M | $48.8M | $22.4M | $17.6M | $16.4M |
| Total assets | — | $10.7M | $436.1M | $380.2M | $306.5M | $242.6M | $147.8M | $59.0M |
| Total liabilities | — | $11.0M | $6.21M | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Long-term debt | — | $5.42M | — | — | $9.39M | $9.64M | $9.47M | $4.53M |
| Shareholders' equity | −$51.8M | −$70.6M | $429.8M | $363.0M | $263.5M | $189.7M | $113.6M | $26.0M |
| Cash flow | ||||||||
| Operating cash flow | −$13.2M | −$14.2M | −$38.3M | −$68.1M | −$89.2M | −$130.4M | −$121.9M | −$84.1M |
| Capital expenditure | $653.0K | $353.0K | $31.0K | $666.0K | $1.43M | $1.27M | $447.0K | $212.0K |
| Free cash flow | −$13.8M | −$14.6M | −$38.3M | −$68.8M | −$90.7M | −$131.6M | −$122.4M | −$84.4M |
| Share buybacks | $6.00K | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$32.6M | −$30.6M | −$31.8M | −$26.6M | −$22.5M | −$23.0M | −$19.0M | −$18.0M |
| Net income | −$30.7M | −$29.2M | −$30.8M | −$25.9M | −$22.1M | −$22.8M | −$17.9M | −$18.0M |
| EPS (diluted) | −$0.58 | −$0.53 | −$0.58 | −$0.49 | −$0.41 | −$0.42 | −$0.17 | −$0.13 |
| Balance sheet | ||||||||
| Cash and equivalents | $16.1M | $17.6M | $20.6M | $19.3M | $23.4M | $16.4M | $32.3M | $22.7M |
| Total assets | $185.7M | $147.8M | $120.9M | $95.3M | $82.7M | $59.0M | $178.3M | $160.8M |
| Total liabilities | $48.9M | $34.2M | $32.6M | $30.9M | $37.9M | $33.1M | $27.0M | $24.6M |
| Long-term debt | $9.84M | $9.47M | $8.23M | $7.00M | $5.76M | $4.53M | $3.29M | $9.71M |
| Shareholders' equity | $136.8M | $113.6M | $88.3M | $64.4M | $44.8M | $26.0M | $151.3M | $136.2M |
| Cash flow | ||||||||
| Operating cash flow | −$25.4M | −$32.0M | −$24.7M | −$23.4M | −$17.1M | −$19.0M | −$18.6M | −$16.1M |
| Capital expenditure | $149.0K | $60.0K | $60.0K | $47.0K | $56.0K | $49.0K | $50.0K | $17.0K |
| Free cash flow | −$25.5M | −$32.1M | −$24.7M | −$23.5M | −$17.1M | −$19.0M | −$18.7M | −$16.1M |
From ALX Oncology Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning ALX Oncology Holdings in our feed yet.